Crystal NAX, part of Crystal Group

About Crystal NAX, part of Crystal Group

Crystal NAX (Crystal Nucleic Acid Excellence), a wholly owned business of Crystal Group, is an integrated partner for RNA therapeutics and non-viral delivery. We bring the full nucleic acid workflow together under one team — RNA and DNA synthesis and production, LNP/t-LNP formulation, comprehensive analytical characterization, and CMC development to GMP supply — moving programs from concept to clinic, quickly and cost-effectively. NAX is incorporated in Delaware, US with operations in Cranbury, NJ, Boston, MA and Suzhou, China. Core capabilities: RNA Design & Production: mRNA, saRNA, circRNA, sgRNA, and other therapeutic RNA modalities. LNP Formulation & Delivery: custom xLNP and t-LNP formulation, high-throughput screening and optimization, including targeted delivery to support in-vivo CAR-T and other cell-specific applications. Analytical Characterization: routine and extended characterization of RNA and LNPs. CMC for IND/IIT: customized process and analytical development packages for smooth IND/IIT-enabling production and rigorous quality control. Catalog Products & Reagents: off-the-shelf products and reagents ready for R&D use. We partner with academic researchers, biotech innovators, and global pharmaceutical leaders to transform nucleic acid science into therapies that shape the future of medicine.